Given a paragraph and a claim, classify it this way: If the claim contradicts the evidence present in the paragraph, classify the claim as '0'. If the claim has multiple supporting *AND* contradicting evidences, classify the claim as '1'. If the claim has supporting evidence and the paragraph is in overall favor of the claim, then classify the claim as '2'.
--------
Question: Paragraph: The ruling Communist Party's Politburo said on Friday it would step up macroeconomic policy adjustments and pursue more proactive fiscal policy, state media reported. With the world's second-biggest economy expected to shrink for the first time in four decades this quarter, China is set to unleash hundreds of billions of dollars in stimulus. The Politburo called for expanding the budget deficit, issuing more local and national bonds, guiding interest rates lower, delaying loan repayments, reducing supply-chain bottlenecks and boosting consumption. "We expect government ministries to roll out more tangible measures in the coming weeks as this Politburo meeting gave them no choice but to do more," Goldman Sachs analysts said. The Politburo did not elaborate on plans for the central government to issue special treasury bonds, which would be the first such issuance since 2007. China should issue at least 2 trillion yuan ($282 billion) of such bonds to aid the economy, Morgan Stanley Chief China Economist Robin Xing said. Restrictions on foreigners entering the country went into effect on Saturday, as China reported no new locally transmitted infections and a small drop in so-called imported cases. Airlines have been ordered to sharply cut international flights from Sunday. Beijing has in recent days emphasized the risk posed by imported virus cases after widespread lockdowns within China helped to sharply reduce domestic transmissions. The Politburo said it would shift its focus to prevent more imported cases and a rebound in locally transmitted infections. "We must be extremely vigilant and cautious, and we must prevent the post-epidemic relaxation from coming too soon, leading to the loss of all our achievements," the Communist Party's official People's Daily newspaper said in a front-page editorial. The authorities also reversed planned reopenings of movie theaters, the state-owned China Securities Journal reported, citing sources. With local transmission of the virus basically under control, China shifts focus toward rebooting paused businesses. China's Ministry of Commerce said on Saturday nearly all of the country's major supermarkets, convenience stores, shopping malls and farm produce retail markets have reopened, while all e-commerce platforms are operating. Meanwhile, 80% of restaurants and 60% of hotels are back in business, ministry official Wang Bin told a news conference. In a sign of businesses getting back to normal, wholesale prices of vegetables have dropped 16.5% from end-February, while pork prices have fallen 7.4% from a mid-February high. However, many street shops such as beauty salons are not yet open as "sentiment is reviving slowly, while people remain cautious about going out shopping", Wang said. In China's central Hubei Province, authorities had removed all highway checkpoints except those in its capital city Wuhan - the virus epicenter - and allowed traffic to leave the province as of Friday, the official Xinhua News Agency reported on Saturday. Hubei officials vowed to help businesses re-open and people get back to work. Gong Dingrong, mayor of Hubei's Qianjiang, dubbed "lobster city", said the government would promote sales across the country both online and offline, adding "there's nothing to fear" eating lobsters from the city. China's National Health Commission said on Saturday that 54 new coronavirus cases were reported on the mainland on Friday, all imported cases. There were 55 new cases a day earlier, one of which was transmitted locally. The number of infections for mainland China stands at 81,394, with the death toll rising by three to 3,295, the commission said. Hubei province reported no new cases, and three new deaths. The province of 60 million, where the virus was first detected, has recorded 67,801 coronavirus cases and 3,177 deaths. Shanghai reported the highest number of new cases, with 17. An additional 11 cases were reported in Guangdong, six in Fujian, five in Tianjin, four in Zhejiang, three each in Beijing and Liaoning, two each in Inner Mongolia and Jilin, and one in Shandong. Chinese President Xi Jinping told U.S. President Donald Trump on Friday that China would support U.S. efforts to fight the coronavirus. The number of confirmed cases of coronavirus in the United States rose by at least 16,000 on Friday to nearly 102,000, the most of any country. George Gao, the director-general of the Chinese Center for Disease Control and Prevention, urged people to wear masks to control the virus's spread overseas. Gao told the journal Science in an interview published on Friday that the "big mistake in the United States and Europe has been the failure to wear masks, which "can prevent droplets that carry the virus from escaping and infecting others". Claim: China readies stimulus measures as local virus cases dwindle.

Answer: 2

Question: Paragraph: An old hoax aboutCharles Manson beingparoled that was started by a known fake news website in June 2014 resurfaced in June 2017. The rumor stems from a 2014 report that appeared at Empire News under the headline, "Charles Manson Granted Parole," that reports Manson had been granted paroledue to prison overcrowding: The ruling, issued by three judges overseeing the state's efforts to ease theovercrowding, gives California until February 2016 to achieve their goals. But, thejudges said, the state has to make elderly inmates and those with serious illnesseseligible for parole immediately. Manson, who was denied parole in April of 2012 and wasn't scheduled for anotherparole hearing until 2027, was re-evaluated due to his age and health and the ParoleBoard recommended his parole. The site's disclaimer, however, states that it's content is "intended for entertainment purposes only," meaning that its reporting should not be taken as fact. It's not clear why Charles Manson parole rumors resurfaced in June 2017. Manson was denied parole by the California Department of Corrections in 2012 and his next parole hearing was scheduled for 2027, when Manson would be 92 years old. In January 2017, however, Manson was transferred to a hospital for treatment of gastrointestinal bleeding, and Manson's condition was described as "serious" by family members. He had been transferred back toprison by the time the rumor resurfaced. It's possible that parole decisions regarding the release of other former Manson Family members could have contributed to CharlesManson parole rumors resurfacing. A panel recommended the release ofa former Manson Family member named Bruce Davis who murderedmusician Gary Hinman andstuntman Donald "Shorty" Shea in 1969. The final decision, however, will rest with California Gov. JerryBrown, who had about five months to make a decision. the Los Angeles Times reports. Meanwhile, an appeals panel postponed a decision on wether or not to recommend the release of former Manson Family memberPatricia Krenwinkel in December 2016, Fox News reports. Krenwinkel was present at the 1969 murder of Sharon Tate and four others. But regardless ofdevelopments with other members of the Manson Family, all Charles Manson parole rumors should be considered "fiction" until at least 2027, when his next hearing is scheduled. Comments Claim: Charles Manson has been granted parole and will be released from prison.

Answer: 0

Question: Paragraph: Abbott executives said the increase in manufacturing capacity will begin in the second half of this year and make room for the expected U.S. launch of the FreeStyle Libre 2. This next-generation device has been approved in Europe and is now under U.S. regulatory review. Abbott's plans for Libre, its fastest-growing diabetes product, used by 1.5 million people worldwide, will be in focus when the company reports quarterly earnings on Wednesday. Jared Watkin, Abbott's senior vice president for Diabetes Care, said in an interview that scale is a "huge part" of the company's strategy for its glucose monitors. "When you're making disposable diagnostic products, the more you can make, the lower the cost you can produce them at." While the Libre 2 has more features, including alarms for when blood sugar levels swing too low or high, Abbott plans to keep the U.S. price the same as its predecessor, Watkin said. Abbott started in diabetes care as a maker of inexpensive test strips and glucose meters. More recently, the company has sought to expand access to its so-called continuous glucose monitoring (CGM) devices - traditionally sold to type 1 diabetics in markets with generous insurance coverage. "It's not good enough to bring this to a small, wealthy population. Diabetes is such a global epidemic that you need to bring products that can really make a dent in that," Watkin said. Launched in Europe in 2014 and in the United States three years later, the FreeStyle Libre allows people with diabetes to track blood sugar levels without multiple daily finger sticks. A sensor attached to the back of the upper arm uses a thin filament under the skin to measure glucose every minute. Users check their blood sugar levels throughout the day by waving a reader, or smartphone, over the sensor. Major competitors Medtronic Plc (MDT.N) and Dexcom Inc (DXCM.O) critique the current Libre's lack of automatic alerts that can help diabetics manage their disease. Yet they also are taking steps to introduce cheaper models themselves, executives told Reuters. Libre's sales are expected to reach $1.5 billion this year, the company said. In April, Goldman Sachs estimated the global CGM market could reach $5 billion by 2021, up from $3.7 billion in 2019. Goldman projected Abbott's 2021 sales at $2.7 billion compared to $1.7 billion for Dexcom and $894 million for Medtronic. In the past, CGMs were used almost exclusively by type 1 diabetics, whose bodies do not make insulin and who must inject themselves with the blood-sugar regulating hormone to survive. Increasingly, people with type 2 diabetes - the kind driven by obesity, lack of exercise and genetics - must also closely monitor their blood glucose and use insulin to manage their disease when it is not controlled by other medications and lifestyle changes. For now, Libre users include 1 million type 1 diabetic patients and half a million type 2. That's a tiny sliver of the 425 million people with diabetes worldwide. Although not all diabetics need glucose monitors, "there is an element of scratching the surface at this point," Watkin said. "The need to invest and bring up capacity is, we believe, going to be an ongoing activity for us." Two 14-day Libre sensors, a month's supply, retail for $109. Abbott says most of its patients are commercially insured, and many pay as little as $10 out of pocket. In the United States, the company says, more than half of people in commercial health plans are covered, as well as any eligible diabetic person on Medicare, the federal program for the elderly and disabled. The device is also approved in 45 other countries, including Germany, Japan, Brazil, China and the United Arab Emirates. Medtronic told Reuters it offers a discounted price of $345 per month for uninsured patients. The company estimates that the typical insured patient pays $50 a month. Medicare does not cover the device. Dexcom's G6 sensors retail online, with a discount, at around $350 for a month's supply. Dexcom says 98 percent of all U.S. private insurers cover the device, and patients covered by commercial insurance pay an average of $50-$80 per month for sensors through pharmacies or durable medical equipment suppliers. It is covered by Medicare. Libre's 14-day sensor is also longer-lasting. Dexcom's sensors work for 10 days, and Medtronic's for up to 7. Abbott was also the first company to introduce a product that can be used without routine finger stick tests to validate the sensor's readings a feature Dexcom later matched and Medtronic has not. Dr. Roy Beck, an endocrinologist at the Jaeb Center for Health Research in Tampa, Florida, said that Abbott's FreeStyle Libre is "an excellent sensor" but not as accurate at detecting very low blood sugar as the devices from Dexcom, Medtronic or an implantable CGM made by Senseonics (SENS.A). That makes it less desirable for patients for whom this is a major issue, he said. Beck's center has received research funding from Abbott and Dexcom. Medtronic and Dexcom executives say the current Libre does not compare with their devices when it comes to features such as alerting users to dangerous blood sugar changes and providing comprehensive trend data. "It's the cheapest, but it's not exactly in the same category," said Mike Hill, vice president and general manager of Medtronic's sensor business. Abbott countered that its sensor has best-in-class accuracy, and noted that the next-generation Libre 2 does have optional alarms. Still, Medtronic is considering making a cheaper sensor for patients who don't need all the features of its current continuous monitor, Hill said. And next year, Dexcom plans to launch a cheaper, smaller, 14-day sensor developed in partnership with Verily, Alphabet Inc's (GOOGL.O) life sciences division. Dexcom Chief Executive Kevin Sayer acknowledged that Abbott's pricing strategy will affect the global market over time, and that Dexcom expects its own prices to come down. "We've planned for this," he said. Claim: You see a whole bunch of Korean cars here in the United States, and you don't see any American cars in Korea.

Answer:
2